TABLE 2.

Summary of Antimicrobial Peptides in Clinical Development for Nonocular Applications

Synthetic compound	Company	AMP type (Species)	Clinical trial outcomes	Planned clinical trials
Pexiganan (MSI-78)	Genaera Plymouth Meeting, PA (formerly Magainin Pharmaceutical Inc.)	Magainin 2 (Xenopus frog)	No advantage over conventional antibiotics in a Phase III trial for topical Rx of diabetic foot ulcers. Failed to gain FDA approval.	None.
Iseganan (IB-367)	Intrabiotics Pharmaceuticals, Inc. Mountainview, CA	Protegrin (Pig)	Failed two Phase III trials as mouthrinse for stomatitis in highrisk patients. Failed Phase III trial as aerosolized Rx in ventilator-associated pneumonia.	Phase IIa trial as aerosolized Rx for CF patients with chronic respiratory infections.
Omiganan (MBI-226)	Microbiologix Biotech Vancouver, BC	Indolicidin (Bovine)	Failed Phase III trial as topical Rx to prevent or reduce venous catheter-related bloodstream infections.	Repeat Phase III trial to confirm reduction in catheter colonization and local infections under consideration.
MBI 594AN	Microbiologix Biotech Vancouver, BC, Canada	Indolicidin (Bovine)	Phase IIb trial showed efficacy as topical Rx for acne.	Phase III trial.
P113 P113D	Demegen, Pittsburgh, PA Dow Pharmaceutical Sciences, Patuloma, CA	Histatins (Human)	Completed Phase II trial as mouthrinse for oral candidiasis in HIV patients.	Inhalation Rx for Pseudomonas infections in CF patients under consideration.
XMP.629	Xoma (US) Berkeley, CA	BPI (Human)	Failed Phase III trial as topical Rx for acne.	None at present time.
Neuprex (rBPI21)	Xoma (US) Berkeley, CA	BPI (Human)	Failed Phase III trial as adjunctive parenteral Rx to reduce mortality in pediatric meningococcemia.	Planned Phase I/II trial to reduce inflammatory complications in pediatric open heart-surgery patients.